Related Experiment Videos
Tolerability and side-effect profile of rhIL-11
1Clinic Research Earle A. Chiles Research Institute, Providence Portland Medical Center, Oregon, USA. jsmith3@providence.org
Oncology (Williston Park, N.Y.)
|October 18, 2000
Summary
Recombinant human interleukin-11 (rhIL-11) effectively mitigates chemotherapy-induced thrombocytopenia in cancer patients. This therapy demonstrates an acceptable safety profile, with manageable side effects, making it a viable treatment option.
Area of Science:
- Oncology
- Hematology
- Pharmacology
Background:
- Chemotherapy often leads to thrombocytopenia, increasing bleeding risk.
- Recombinant human interleukin-11 (rhIL-11), also known as oprelvekin, is investigated for managing this side effect.
Purpose of the Study:
- To evaluate the safety and tolerability of rhIL-11 in adult and pediatric patients with nonmyeloid malignancies undergoing chemotherapy.
Main Methods:
- Data from two randomized phase II and one phase III placebo-controlled, double-blind clinical studies.
- Inclusion of adult and pediatric patients with nonmyeloid malignancies.
Main Results:
- rhIL-11 demonstrated an acceptable toxicity profile for mitigating chemotherapy-induced thrombocytopenia.
- Adverse events were generally mild, reversible, and manageable, with common events related to fluid retention.
- No increased incidence of adverse events or bone marrow exhaustion observed with sequential rhIL-11 cycles.
- No adverse interactions noted with concurrent chemotherapy or supportive care agents like G-CSF.
Conclusions:
- rhIL-11 is a well-tolerated therapy for chemotherapy-induced thrombocytopenia in cancer patients.
- Medically managed fluid retention-related adverse events do not limit rhIL-11 use.
- rhIL-11 can be safely administered with chemotherapy and supportive care agents.